Loading...
Loading...
HLVX| Name | Value |
|---|---|
| Revenues | 2.9M |
| Cost of Revenue | 0.7M |
| Gross Profit | 2.1M |
| Operating Expense | 39.6M |
| Operating I/L | -40.3M |
| Other Income/Expense | 3.3M |
| Interest Income | 3.0M |
| Pretax | -37.0M |
| Income Tax Expense | 2.7M |
| Net Income/Loss | -37.0M |
HilleVax, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of novel vaccines. Their primary focus is on the development of HIL-214, a virus-like particle-based vaccine candidate designed to prevent moderate-to-severe acute gastroenteritis caused by norovirus infection. The company's revenue model is centered around the research, development, and eventual commercialization of their vaccine products, with a focus on addressing unmet medical needs in the field of infectious diseases.
